Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang
- DOI
- 10.1136/annrheumdis-2021-220788
- Published
- 2023-07
- Container
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1136/annrheumdis-2021-220788,
title = {Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang},
author = {James Cheng-Chung Wei and Tae-Hwan Kim and Mitsumasa Kishimoto and Naoki Ogusu and Haeyoun Jeong and Shigeto Kobayashi},
year = {2023},
journal = {Annals of the Rheumatic Diseases},
doi = {10.1136/annrheumdis-2021-220788},
url = {https://doi.org/10.1136/annrheumdis-2021-220788}
}RIS
TY - JOUR TI - Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang AU - James Cheng-Chung Wei AU - Tae-Hwan Kim AU - Mitsumasa Kishimoto AU - Naoki Ogusu AU - Haeyoun Jeong AU - Shigeto Kobayashi PY - 2023 JO - Annals of the Rheumatic Diseases DO - 10.1136/annrheumdis-2021-220788 UR - https://doi.org/10.1136/annrheumdis-2021-220788 ER -
APA
Wei, J. C., Kim, T., Kishimoto, M., Ogusu, N., Jeong, H., & Kobayashi, S. (2023). Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2021-220788
Source records
- crossref · retrieved 2026-09-27T01:40:01.917Z